Navigating patient access challenges when bringing your CGT product to market
Cell and gene therapies (CGTs) are transformative modalities in personalized medicine. These groundbreaking advancements address unmet needs for life-threatening or debilitating conditions that have limited or no curative options. But manufacturers often find it challenging to commercialize CGTs successfully, with one major set of challenges involving patient access.
Enter your information to access recommendations intended to help you navigate these challenges so you can deliver on your CGT’s potential to improve patient lives.
Fill out the form below to access recommendations
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.